Please check your internet connection and try again.
# Amoxicillin-Clavulanate
## Overview
Amoxicillin-clavulanate is a combination penicillin-class antibiotic consisting of a beta-lactam (amoxicillin) and a beta-lactamase inhibitor (clavulanate potassium). The addition of clavulanate extends the spectrum of activity to include beta-lactamase-producing organisms (e.g., *H. influenzae*, *M. catarrhalis*, *S. aureus*).
## Primary Indications
Common indications include acute bacterial rhinosinusitis, community-acquired pneumonia, otitis media, bite wounds, and skin/soft tissue infections.
## Adult Dosing
Standard dosing is based on the amoxicillin component.
* **Mild to Moderate Infections:** 500 mg amoxicillin/125 mg clavulanate every 8 hours OR 875 mg amoxicillin/125 mg clavulanate every 12 hours.
* **Severe Infections/Respiratory Tract:** 875 mg amoxicillin/125 mg clavulanate every 12 hours.
* **ER/Extended Release:** 2000 mg amoxicillin/125 mg clavulanate every 12 hours (indicated for resistant *S. pneumoniae*).
## Pediatric Dosing
Dosing is based on the weight of the patient and the amoxicillin component. Guidelines vary by local epidemiology (e.g., suspected pneumococcal resistance); always verify against local institutional antibiograms.
* **Standard dose:** 20–45 mg/kg/day (amoxicillin component) divided every 8–12 hours.
* **High dose (e.g., Otitis Media):** 80–90 mg/kg/day (amoxicillin component) divided every 12 hours, using the 7:1 or 14:1 formulation to minimize clavulanate-related diarrhea.
* **Note:** Use caution with the 125 mg/5 mL suspension as it contains more clavulanate per dose than higher-concentration suspensions.
## Dose Adjustments
* **Renal Impairment:** Reduce dose or increase interval if CrCl < 30 mL/min. Avoid the 875 mg/125 mg tablet in patients with severe renal impairment (CrCl < 30 mL/min).
* **Hepatic Impairment:** Use with caution; monitor hepatic function.
## Contraindications
* History of serious hypersensitivity (e.g., anaphylaxis, Stevens-Johnson syndrome) to amoxicillin, clavulanate, or other penicillins.
* History of cholestatic jaundice or hepatic dysfunction associated with amoxicillin-clavulanate.
## Adverse Effects
* **Common:** Diarrhea (frequently clavulanate-related), nausea, vomiting, skin rash.
* **Serious:** *C. difficile*-associated diarrhea, hepatotoxicity (cholestatic jaundice), severe hypersensitivity reactions.
## Key Drug Interactions
* **Warfarin:** May increase the anticoagulant effect (INR monitoring recommended).
* **Methotrexate:** May decrease renal clearance, potentially increasing methotrexate toxicity.
* **Probenecid:** Decreases renal tubular secretion of amoxicillin, increasing serum levels.
## Monitoring
* **Renal/Hepatic:** Monitor renal function in moderate/severe impairment; monitor LFTs with prolonged therapy.
* **Allergy:** Assess for signs of hypersensitivity during initial doses.
* **Gastrointestinal:** Monitor for persistent diarrhea or signs of *C. diff* infection.
## Clinical Pearls
* **GI Tolerability:** Administer with food to reduce gastrointestinal side effects.
* **Formulation Warning:** Do not use 250 mg or 500 mg tablets interchangeably with extended-release formulations or high-strength powders, as the clavulanate content varies significantly to avoid toxicity.
* **Resistance:** Overuse of the 125 mg clavulanate component in pediatric formulations contributes to dose-dependent diarrhea; always select the formulation that satisfies the amoxicillin dose while minimizing excess clavulanate.
***
*Disclaimer: This information is for educational purposes only. Dosing, contraindications, and interaction profiles may change. Always verify current prescribing information via official manufacturer labeling or authoritative clinical databases before prescribing or administering medication.*
